Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Kidney Int

Retrieve available abstracts of 41 articles:
HTML format

Single Articles

    July 2021
  1. IKEDA Y
    Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23.
    Kidney Int. 2021;100:14-16.
    PubMed     Abstract available

  2. ARICETA G, Dixon BP, Kim SH, Kapur G, et al
    The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment.
    Kidney Int. 2021;100:225-237.
    PubMed     Abstract available

    June 2021
  3. KOYUN M, Kaya Aksoy G, Comak E, Ozaltin F, et al
    Outcome of diacylglycerol kinase epsilon-mediated hemolytic uremic syndrome in an infant.
    Kidney Int. 2021;99:1500-1501.

    April 2021
  4. BABITT JL, Eisenga MF, Haase VH, Kshirsagar AV, et al
    Controversies in Optimal Anemia Management: Conclusions from a Kidney Disease Improving Global Outcomes (KDIGO) Conference.
    Kidney Int. 2021 Apr 8. pii: S0085-2538(21)00355.
    PubMed     Abstract available

    March 2021
  5. HANUDEL MR, Wong S, Jung G, Qiao B, et al
    Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Kidney Int. 2021 Mar 31. pii: S0085-2538(21)00354.
    PubMed     Abstract available

  6. FUCHS MAA, Broeker KAE, Schrankl J, Burzlaff N, et al
    Inhibition of transforming growth factor beta1 signaling in resident interstitial cells attenuates profibrotic gene expression and preserves erythropoietin production during experimental kidney fibrosis in mice.
    Kidney Int. 2021 Mar 8. pii: S0085-2538(21)00278.
    PubMed     Abstract available

    January 2021
  7. VILLE S, Le Bot S, Chapelet-Debout A, Blancho G, et al
    Atypical HUS relapse triggered by COVID-19.
    Kidney Int. 2021;99:267-268.

    November 2020
  8. NORIS M, Remuzzi G
    Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?
    Kidney Int. 2020;98:1084-1087.
    PubMed     Abstract available

  9. HASSANEIN M, Liaqat A, Paratore DA, Vachharajani TJ, et al
    The Case | Arrhythmias in a patient with sickle cell disease on hemodialysis.
    Kidney Int. 2020;98:1357-1358.

    May 2020
  10. BROEKER KAE, Fuchs MAA, Schrankl J, Kurt B, et al
    Different subpopulations of kidney interstitial cells produce erythropoietin and factors supporting tissue oxygenation in response to hypoxia in vivo.
    Kidney Int. 2020 May 23. pii: S0085-2538(20)30542.
    PubMed     Abstract available

    April 2020
  11. WYATT CM, Drueke TB
    Inhibition of HIF prolyl-hydroxylase domain to correct anemia in patients with chronic kidney disease.
    Kidney Int. 2020;97:639-642.

    December 2019
    Ferric citrate: cardio- and renoprotective in chronic kidney disease?
    Kidney Int. 2019;96:1277-1279.
    PubMed     Abstract available

    November 2019
  13. EL KAROUI K, Boudhabhay I, Fremeaux-Bacchi V
    Atypical hemolytic uremic syndrome and hypertensive crisis.
    Kidney Int. 2019;96:1239.

    July 2019
  14. ELABD H, Rashid T, Elkholi M, Stokes MB, et al
    The Case | Acute kidney injury in an African woman with microangiopathic hemolytic anemia and HIV.
    Kidney Int. 2019;96:253-254.

    June 2019

  15. Wyatt CM, Drueke TB. High-dose IV iron for anemia correction in chronic kidney disease. Kidney Int. 2019;95:727-730.
    Kidney Int. 2019;95:1518.

    May 2019
  16. CAVERO T, Arjona E, Soto K, Caravaca-Fontan F, et al
    Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome.
    Kidney Int. 2019 May 31. pii: S0085-2538(19)30582.
    PubMed     Abstract available

  17. CHO ME, Hansen JL, Peters CB, Cheung AK, et al
    An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease.
    Kidney Int. 2019 May 15. pii: S0085-2538(19)30506.
    PubMed     Abstract available

  18. SELVASKANDAN H, Karavadra M, Paramesparan K, Glasby M, et al
    The Case | Microangiopathic hemolytic anemia in a young female.
    Kidney Int. 2019;95:1277-1278.

    April 2019
  19. WYATT CM, Drueke TB
    High-dose IV iron for anemia correction in chronic kidney disease.
    Kidney Int. 2019;95:727-730.

  20. DUINEVELD C, Wijnsma KL, Volokhina EB, van den Heuvel LPB, et al
    Placental passage of eculizumab and complement blockade in a newborn.
    Kidney Int. 2019;95:996.

    March 2019
    Iron and oxygen sensing: discovering intricate links.
    Kidney Int. 2019;95:482-484.

    February 2019
  22. ZECHER D, Banas B, Buttner-Herold M, Kirschfink M, et al
    The Case | A 78-year-old woman with acute kidney injury and hemolytic anemia.
    Kidney Int. 2019;95:473-474.

  23. IMERI F, Nolan KA, Bapst AM, Santambrogio S, et al
    Generation of renal Epo-producing cell lines by conditional gene tagging reveals rapid HIF-2 driven Epo kinetics, cell autonomous feedback regulation, and a telocyte phenotype.
    Kidney Int. 2019;95:375-387.
    PubMed     Abstract available

    January 2019
  24. LEE CJ, Smith DW, Gardiner BS, Evans RG, et al
    Stimulation of erythropoietin release by hypoxia and hypoxemia: similar but different.
    Kidney Int. 2019;95:23-25.
    PubMed     Abstract available

    November 2018
  25. MONTERO D, Lundby C
    Arterial oxygen content regulates plasma erythropoietin independent of arterial oxygen tension: a blinded crossover study.
    Kidney Int. 2018 Nov 29. pii: S0085-2538(18)30718.
    PubMed     Abstract available

  26. GANZ T
    Erythropoietin and iron-a conflicted alliance?
    Kidney Int. 2018;94:851-853.
    PubMed     Abstract available

    September 2018
  27. SUZUKI N, Matsuo-Tezuka Y, Sasaki Y, Sato K, et al
    Iron attenuates erythropoietin production by decreasing hypoxia-inducible transcription factor 2alpha concentrations in renal interstitial fibroblasts.
    Kidney Int. 2018 Sep 20. pii: S0085-2538(18)30515.
    PubMed     Abstract available

    June 2018
  28. ANUSORNVONGCHAI T, Nangaku M, Jao TM, Wu CH, et al
    Palmitate deranges erythropoietin production via transcription factor ATF4 activation of unfolded protein response.
    Kidney Int. 2018 Jun 7. pii: S0085-2538(18)30250.
    PubMed     Abstract available

    February 2018
  29. MERINERO HM, Garcia SP, Garcia-Fernandez J, Arjona E, et al
    Complete functional characterization of disease-associated genetic variants in the complement factor H gene.
    Kidney Int. 2018;93:470-481.
    PubMed     Abstract available

  30. HUERTA A, Arjona E, Portoles J, Lopez-Sanchez P, et al
    A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome.
    Kidney Int. 2018;93:450-459.
    PubMed     Abstract available

    January 2018
  31. TORO L, Barrientos V, Leon P, Rojas M, et al
    Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury.
    Kidney Int. 2018 Jan 27. pii: S0085-2538(17)30854.
    PubMed     Abstract available

    July 2017
  32. BROCKLEBANK V, Johnson S, Sheerin TP, Marks SD, et al
    Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.
    Kidney Int. 2017 Jul 24. pii: S0085-2538(17)30323.
    PubMed     Abstract available

    June 2017
  33. SUGAHARA M, Tanaka T, Nangaku M
    Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
    Kidney Int. 2017 Jun 24. pii: S0085-2538(17)30305.
    PubMed     Abstract available

  34. VAN LAECKE S, Van Biesen W
    Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect?
    Kidney Int. 2017;91:1271-1274.
    PubMed     Abstract available

    March 2017
  35. GOODSHIP TH, Cook HT, Fakhouri F, Fervenza FC, et al
    Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Kidney Int. 2017;91:539-551.
    PubMed     Abstract available

    November 2016
  36. RHEAULT MN, Molony JT, Nevins T, Herzog CA, et al
    Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis.
    Kidney Int. 2016 Nov 16. pii: S0085-2538(16)30539.
    PubMed     Abstract available

  37. WYATT CM, Drueke TB
    HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
    Kidney Int. 2016;90:923-925.
    PubMed     Abstract available

    September 2016
  38. PERGOLA PE, Spinowitz BS, Hartman CS, Maroni BJ, et al
    Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Kidney Int. 2016 Sep 17. pii: S0085-2538(16)30357.
    PubMed     Abstract available

    July 2016
  39. VANKALAKUNTI M, Vasavi B, Anitha A
    Intravascular large B-cell lymphoma: masquerade as membranoproliferative glomerulonephritis.
    Kidney Int. 2016;90:231-2.

    May 2016
  40. MARCELLI D, Bayh I, Merello JI, Ponce P, et al
    Dynamics of the erythropoiesis stimulating agent resistance index in incident hemodiafiltration and high-flux hemodialysis patients.
    Kidney Int. 2016 May 10. pii: S0085-2538(16)30056.
    PubMed     Abstract available

    March 2016
  41. GREENBAUM LA, Fila M, Ardissino G, Al-Akash SI, et al
    Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
    Kidney Int. 2016;89:701-11.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Anemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.